These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22642877)

  • 21. Phase II study of mifepristone (RU486) in refractory ovarian cancer.
    Rocereto TF; Saul HM; Aikins JA; Paulson J
    Gynecol Oncol; 2000 Jun; 77(3):429-32. PubMed ID: 10831354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
    Brandhagen BN; Tieszen CR; Ulmer TM; Tracy MS; Goyeneche AA; Telleria CM
    BMC Cancer; 2013 Jan; 13():35. PubMed ID: 23351358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
    Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA
    Ponandai-Srinivasan S; Lalitkumar PG; Garcia L; Varghese SJ; Carlson JW; Gemzell-Danielsson K; Floter Radestad A
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):250-261. PubMed ID: 30325501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
    Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
    J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
    Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
    Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Aravantinos G; Fountzilas G; Kosmidis P; Dimopoulos MA; Stathopoulos GP; Pavlidis N; Bafaloukos D; Papadimitriou C; Karpathios S; Georgoulias V; Papakostas P; Kalofonos HP; Grimani E; Skarlos DV;
    Ann Oncol; 2005 Jul; 16(7):1116-22. PubMed ID: 15928071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
    Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
    Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA; Ngo H; Martin MC; Wolf JK
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Grènman S
    Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells.
    Wang G; Shang HL; Xie Y; Xiao P; Li XJ; Lin TC; Li GY
    Chin Med J (Engl); 2005 Feb; 118(4):333-6. PubMed ID: 15740674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.